226 related articles for article (PubMed ID: 16205732)
1. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
[TBL] [Abstract][Full Text] [Related]
2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
3. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
4. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
5. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
6. Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
Kim YJ; Kim DW; Lee S; Chung NG; Hwang JY; Kim YL; Min CK; Kim CC
Bone Marrow Transplant; 2004 Mar; 33(5):535-42. PubMed ID: 14716340
[TBL] [Abstract][Full Text] [Related]
7. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
8. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
[TBL] [Abstract][Full Text] [Related]
11. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
12. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
13. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib].
Han W; Liu KY; Xu LP; Chen H; Liu DH; Chen YH; Zhang XH; Zhang YC; Chen Y; Wang Y; Wang J; Lu DP; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1974-7. PubMed ID: 19062738
[TBL] [Abstract][Full Text] [Related]
16. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
17. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
19. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
[TBL] [Abstract][Full Text] [Related]
20. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
